Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is presented as the stronger 2026 investment case after FY2025 revenue rose 9.9% to nearly $36.7B, net income reached about $7.7B, and free cash flow was approximately $8.1B. Moderna's FY2025 revenue fell 39.2% to roughly $1.9B, while it posted a $2.8B net loss and negative $2.1B free cash flow amid continued pipeline spending. The article favors Amgen's profitable, dividend-supported portfolio and raised outlook over Moderna's higher-risk mRNA pipeline, despite a positive FDA advisory recommendation for Moderna's flu vaccine.

Analysis

The relevant AMGN debate is not earnings durability but whether its acquisition-funded leverage converts modest revenue growth into equity-value fragility if rates remain elevated or legacy-franchise erosion accelerates. Its distributor concentration is less a near-term credit risk than a negotiating-power issue: the large wholesalers can extract economics through working-capital terms and service fees, limiting gross-to-net improvement. A sharper biosimilar inflection would also benefit lower-cost competitors and potentially increase volume handled by MCK, COR, and CAH without providing equivalent profit protection to AMGN.

MRNA’s valuation is effectively a series of clinical and commercialization options, not a vaccine-sales multiple. The key 1-3 month catalysts are regulatory decisions, launch uptake for respiratory products, and management’s cash-burn guidance; each can materially alter the implied runway and therefore the probability-weighted value of oncology and combination-vaccine programs. The Merck collaboration makes MRK a cleaner, diversified way to own some mRNA-oncology upside, while ABUS remains a high-beta beneficiary only if intellectual-property economics become more favorable to it.

Consensus likely overweights AMGN’s dividend and underweights the risk that its multiple cannot expand while debt reduction competes with business-development needs. Conversely, consensus skepticism toward MRNA is directionally justified but may be too linear: a credible path to lower annual cash burn is more important than near-term vaccine revenue, because it extends the duration of its pipeline optionality. This is not a broad healthcare signal; it is a capital-structure-versus-duration trade, with AMGN suited to defensive exposure and MRNA appropriate only as a catalyst-driven position.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral pair: long AMGN / short MRNA in equal dollar amounts, sized modestly. The trade monetizes AMGN’s cash-generation advantage while hedging biotech-sector beta; reassess if MRNA guides to materially lower cash burn or reports a clinically meaningful late-stage oncology readout.
• For existing AMGN longs, use strength to cap exposure rather than chase: maintain only if management demonstrates debt paydown alongside intact guidance. Thesis is falsified by a material legacy-product revenue miss, a guidance cut, or credit-spread widening that raises refinancing concerns; these would pressure equity disproportionately versus large-pharma peers.
• Prefer MRK over a directional MRNA long for investors seeking mRNA-oncology exposure over 6-18 months. MRK provides collaboration upside with a diversified earnings base; add only around verified trial or regulatory catalysts, since no article-derived evidence establishes near-term revenue contribution.
• Keep MCK, COR, and CAH on watch as second-order beneficiaries of specialty-drug distribution volumes, but do not initiate solely on this information. Upgrade the thesis only if quarterly disclosures show rising specialty mix, improved operating margin, or better working-capital economics from manufacturer contracts.